Display options
Share it on

Oncoimmunology. 2014 Jan 01;3(1):e27218. doi: 10.4161/onci.27218.

Immunovirotherapy for the treatment of glioblastoma.

Oncoimmunology

Tooba A Cheema, Peter E Fecci, Jianfang Ning, Samuel D Rabkin

Affiliations

  1. Brain Tumor Research Center; Department of Neurosurgery; Massachusetts General Hospital and Harvard Medical School; Boston, MA USA ; Momenta Pharmaceuticals; Cambridge, MA USA.
  2. Brain Tumor Research Center; Department of Neurosurgery; Massachusetts General Hospital and Harvard Medical School; Boston, MA USA.

PMID: 24575383 PMCID: PMC3929360 DOI: 10.4161/onci.27218

Abstract

We have recently described a new murine model of glioblastoma, generated by the implantation of syngeneic glioblastoma stem cells into immunocompetent mice, that recapitulates the salient histopathological and immunological features of the human disease. We employed this model to demonstrate the multifaceted activity of an oncolytic herpes simplex virus genetically modified to express interleukin-12, G47∆-IL12.

Keywords: Treg; cancer stem cells; glioma; herpes simplex virus; interleukin-12; oncolytic virus

References

  1. Oncoimmunology. 2013 Jun 1;2(6):e24612 - PubMed
  2. Cancer Res. 2006 Mar 15;66(6):3294-302 - PubMed
  3. CA Cancer J Clin. 2010 May-Jun;60(3):166-93 - PubMed
  4. Clin Cancer Res. 2007 Aug 15;13(16):4677-85 - PubMed
  5. Neurosurgery. 2012 Aug;71(2):201-22; discussion 222-3 - PubMed
  6. Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12006-11 - PubMed
  7. Cancer Res. 2009 Apr 15;69(8):3472-81 - PubMed
  8. Adv Exp Med Biol. 2012;746:178-86 - PubMed
  9. Neoplasia. 2013 Jun;15(6):591-9 - PubMed

Publication Types

Grant support